NASIM TASHAKKOR: Open Payments
NPI 1164990453 · EVERETT, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$661 in 25 payments from 6 companies in 2025. Trend: 2023 $14 · 2024 $433 · 2025 $661
Food & beverage: $661
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 7 | $249 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $138 |
| Teva Pharmaceuticals USA, Inc. | 7 | $135 |
| Janssen Pharmaceuticals, Inc | 3 | $65 |
| E.R. Squibb & Sons, L.L.C. | 2 | $59 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
Products named: CAPLYTA, ARISTADA, LYBALVI, AUSTEDO XR, INVEGA SUSTENNA, COBENFY, UZEDY, ABILIFY ASIMTUFII.
Industry payments across WA — which companies pay providers there.
